Arkvax
Develops glycoconjugate vaccines for animal health and antimicrobial resistance prevention
Highlights
- New on EvolcAdded 2026-11-13
About Arkvax
ArkVax develops glycoconjugate vaccines using genetically engineered bacteria to produce sugar-based vaccines. Its technology is intended to provide protection against bacterial and zoonotic diseases in animals.
The company serves the animal health market, including livestock vaccine applications. ARKVAX LIMITED is a UK company founded in 2020 and headquartered in London; its team includes vaccine development and bacterial glycoengineering specialists.
Product: Glycoconjugate vaccine technology and vaccine development for animal health.
Jobs at Arkvax
More biotech & pharma companies
Aspire Biosciences
Rare-disease partnering events and a searchable platform matching patient organisations with drug development companiesYoung companyNew on EvolcAspire Laboratories
Contract analytical and microbiological testing for pharmaceutical, cosmetics, veterinary, healthcare and medical-device companiesNew on EvolcAspire Pharma
Specialty and niche generic medicines for patients, healthcare professionals and health systems in the UK and international marketsRemote-friendlyAstute Healthcare
Wholesale distributor of medicines and FMCG health and personal care products to pharmacies, retailers and hospitals in the UKAsymchem
Small-molecule drug development and GMP manufacturing services for biotech and pharmaceutical companies worldwide
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content delivery
- CloudflareHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
Content management
- WebflowHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Hosting
- AWSHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.